|
Prior Information Notice For Pharmaceutical Products – Advance Notification: Separate Procurement Of Medicines For The Cooperation Area Of Eastern Finland. This Is An Advance Notice Of The Upcoming Competition. The Competition Will Be A Joint Procurement For The Eastern Finland Cooperation Area (Northern Savo Welfare Area, South Savo Welfare Area, North Karelia Welfare Area, Central Finland Welfare Area). The Object Of The Procurement Is Medicinal Products And Preparations Comparable To Them. This Procurement Is A Supplementary Pharmaceutical Procurement For The Cooperation Area Of Eastern Finland. The Estimated Value Of The Acquisition Is Around €34 Million. According To A Preliminary Estimate, The Tender Will Be Published In October 2024 (This Is An Estimate And May Change). Fixed-Term Contracts Are Made For The Products To Be Procured. The Future Bidding Will Tentatively Include The Following Atc Groups, And In Accordance With The Preliminary Contract Periods: For The Groups Mentioned Below, The Actual Contract Period Is Three (3) Years, From 1 April 2025 To 31 March 2028, And In Addition One (1) Option Year For The Period: 1 April 2028 To 31 March 2028. .2029 N01ab Halogenated Hydrocarbons (Inhalation Anaesthetics) The Entire Group Is Being Tendered (Including Sevoflurane And Desflurane) V07ay Bone Cements (Other Non-Therapeutic Auxiliary Products) This Is A Tender For Antibiotic-Containing Bone Cements Used In Hip, Knee And Shoulder Replacement Surgeries And Trauma Patient Surgeries. The Competition Does Not Apply To Bone Cements Used In Back Procedures. (In This Section, The Welfare Region Of Central Finland Is Not Included In The Procurement) Å01 Cytostat-Loaded Embolization Microparticles In Chemoembolization Treatment Included In This Section About The Customers Northern Savo Welfare Region And Southern Savo Welfare Region The Actual Contract Period For The Groups Mentioned Below Is One (1) Year, For The Period: 1.4.2025-31.3.2026 And In Addition One (1) Option Year, For The Period: 1.4.2026-31.3.2027 B01ab04 Dalteparin, Heparin Group (Small Molecular Heparin) B01ab05 Enoxaparin, Heparin Group (Small Molecular Heparin) B01ab10 Tinzaparin, Heparin Group (Small Molecular Heparin) J06bc03 Betslotoxumab , Antibacterial Monoclonal Antibodies L01f Monoclonal Antibodies And Antibody Conjugated Medicines The Entire Group Will Be Contested, Except Excluding From The Competition: L01fy02 Nivolumab And Relatlimabi L04aa Selective Immunosuppressants (Note! Atc Codes Have Changed) The Entire Group Will Be Contested, Except Excluding From The Competition: L04aa03- L04aa19 Groups For The Sake Of Clarity, That The Tender Does Not Include: L04aa03 (Atc Code Remains The Same), Antilymphocyte Immunoglobulin Inf.Cons, 50 Mg/1 Ml L04aa04 (Atc Code Remains The Same), Antithymocyte Immunoglobulin Inf.Ka/Liu, 5 Mg/1 Ml L04aa06 (Atc Code Remains The Same), Mycophenolic Acid L04aa10 ==> L04ah01, Sirolimus L04aa13 ==> L04ak01, Leflunomide L04aa18 ==> L04ah02, Everolimus For The Sake Of Clarity, It Is Stated That The Competition Includes: L04aa23 ==> L04ag03, Natalizumab L04aa24 (Atc Code Remains The Same), Abatacept L04aa25 ==> L04aj01, Eculizumab L04aa26 ==> L04ag04, Belimumab L04aa27 ==> L04ae01, Fingolimod L04aa29 ==> L04af01, Tofasiti
|
